Table 2.
Effects of vitamin D3 on serum concentrations of IL-6, hsCRP and NT-proBNP
| Biomarker | Vitamin D3 | Placebo | Difference in change from baselinea | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Geometric mean (SD) |
Change from baseline (ratio), geometric mean (SD) |
N | Geometric mean (SD) |
Change from baseline (ratio), geometric mean (SD) |
Ratio of change from baseline, active to placebo (95% CI) |
p value |
|||
| IL-6 (pg/ml) | ||||||||||
| Baseline | 696 | 1.19 (3.03) | 1.00 (Ref.) | 606 | 1.24 (3.02) | 1.00 (Ref.) | 1.00 (Ref.) | |||
| Year 2 | 530 | 1.31 (3.82) | 1.17 (4.34) | 458 | 1.21 (3.59) | 1.06 (4.49) | 1.10 (0.90, 1.33) | |||
| Year 5 | 495 | 1.18 (3.45) | 1.04 (4.48) | 438 | 1.24 (3.31) | 1.09 (4.44) | 0.96 (0.79, 1.16) | 0.38 | ||
| hsCRP (mg/l) | ||||||||||
| Baseline | 699 | 1.93 (3.22) | 1.00 (Ref.) | 607 | 1.95 (3.02) | 1.00 (Ref.) | 1.00 (Ref.) | |||
| Year 2 | 531 | 1.81 (3.26) | 0.99 (2.6) | 457 | 1.92 (3.01) | 1.02 (2.82) | 0.96 (0.86, 1.09) | |||
| Year 5 | 491 | 1.65 (3.32) | 0.93 (2.71) | 425 | 1.90 (3.36) | 1.03 (3.03) | 0.90 (0.79, 1.03) | 0.33 | ||
| NT-proBNP (ng/l) | ||||||||||
| Baseline | 700 | 246.0 (3.8) | 1.00 (Ref.) | 606 | 281.1 (3.5) | 1.00 (Ref.) | 1.00 (Ref.) | |||
| Year 2 | 530 | 320.2 (4.0) | 1.27 (2.78) | 459 | 304.8 (3.5) | 1.13 (2.7) | 1.12 (0.99, 1.28) | |||
| Year 5 | 496 | 411.4 (4.0) | 1.72 (3.24) | 438 | 369.3 (3.8) | 1.38 (3.02) | 1.24 (1.09, 1.41) | 0.0034 | ||
a
From a linear mixed model that includes adjustment for age, sex, baseline eGFR and baseline urine albumin to creatinine ratio, and accounts for missing data using multiple imputation
p value comes from a global test of the ratio of change from baseline at years 2 and 5 Ref., reference group